share_log

Cowen & Co. Upgrades Takeda Pharmaceutical to Outperform, Raises Price Target to $24

Benzinga Real-time News ·  Jul 19, 2022 07:54

Cowen & Co. analyst Ken Cacciatore upgrades Takeda Pharmaceutical (NYSE:TAK) from Market Perform to Outperform and raises the price target from $21 to $24.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment